Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BACH: Filgotinib vs TNFi Preference in RA
NCT04985435Phase 4Recruiting
- Sponsor
- R-Bos
- Start
- May 2021
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of filgotinib in rheumatoid arthritis (RA) (3 arms), sponsored by R-Bos. Primary endpoints: Proportion of subjects in the first subgroup choosing filgotinib therapy at baseline and Treatment satisfaction at week 24. Started May 2021; status: recruiting.
02
Drugs
filgotinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT04985435.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04985435.